720702-41-0

Basic information

• Product Name: (1-Methyl-1H-pyrazol-5-yl)-boronic acid
• Synonyms: (1-Methyl-1H-pyrazol-5-yl)-boronic acid;Boronic acid, B-(1-methyl-1H-pyrazol-5-yl)-;(1-Methyl-1H-pyrazol-5-yl...;1-Methyl-pyrazole-5-boronic acid;(1-methyl-1H-pyrazol-5-yl)boronic acid(SALTDATA: FREE);1-Methyl-1H-pyrazole-5-boronic acid;1-Methyl-1H-pyrazol-5-yl-5-boronic acid;BORONIC ACID, (1-METHYL-1H-PYRAZOL-5-YL)-
• CAS NO: 720702-41-0
• Molecular Formula: C₄H₇BN₂O₂
• Molecular Weight: 125.922
• Mol File: 720702-41-0.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 323 °C at 760 mmHg
• Flash Point: 149.1 °C
• Appearance: /
• Density: 1.23 g/cm³
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: 8.00±0.58(Predicted)
• CAS DataBase Reference: (1-Methyl-1H-pyrazol-5-yl)-boronic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (1-Methyl-1H-pyrazol-5-yl)-boronic acid(720702-41-0)
• EPA Substance Registry System: (1-Methyl-1H-pyrazol-5-yl)-boronic acid(720702-41-0)

Safety Data

• Statements: 36
• Safety Statements: 26
• Hazardous Substances Data: 720702-41-0(Hazardous Substances Data)

Usage

Uses

1-Methyl-1H-pyrazole-5-boronic Acid acts as a reagent for the design, synthesis and evaluation of novel porcupine inhibitors featuring a fused 3-ring system based on ‘reversed’ amide scaffold.

InChI:InChI=1S/C4H7BN2O2/c1-7-4(5(8)9)2-3-6-7/h2-3,8-9H,1H3

Upstream product

• 930-36-9 1-methyl-1H-pyrazole 
• 5419-55-6 Triisopropyl borate 
• 121-43-7 Trimethyl borate 

Downstream Products

• 847818-74-0 1-methyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyrazole 
• 720702-43-2 5-(2-methoxy-5-nitro-phenyl)-1-methyl-1H-pyrazole 
• 839715-02-5 [3-(2-methyl-2H-pyrazol-3-yl)-4-trifluoromethoxyphenyl]carbamic acid tert-butyl ester 
• 1085386-27-1 5-(2-methyl-2H-pyrazol-3-yl)-2-(2,4,6-trimethylphenylamino)-benzamide 
• 1159186-87-4 5-(4-bromo-2-fluoro-benzyl)-1-methyl pyrazole 
• 1159186-42-1 5-bromo-2-(1-methyl-1H-pyrazol-5-yl)benzonitrile 
• 1159186-49-8 5-(4-bromo-2-methylphenyl)-1-methyl-1H-pyrazole 
• 1159185-54-2 4-(3-{[2-chloro-4-(1-methyl-1H-pyrazol-5-yl)phenyl]thio}phenyl)tetrahydro-2H-pyran-4-carboxamide 
• 1285515-05-0 5-(1-methyl-1H-pyrazol-5-yl)-2-[(phenylmethyl)oxy]-N-3-pyridinylbenzamide 
• 1285515-03-8 2-{[(4-fluorophenyl)methyl]oxy}-5-(1-methyl-1H-pyrazol-5-yl)-N-3-pyridinylbenzamide 
• 1354786-74-5 5-[4-(benzyloxy)biphenyl-3-yl]-1-methyl-1H-pyrazole 
• 1365239-05-9 N-cyclopropyl-2-methyl-4-{8-[(2-methylpropyl)amino]-6-(1-methyl-1H-pyrazol-5-yl)imidazo[1,2-b]pyridazin-3-yl}benzamide 
• 1365238-95-4 N-cyclopropyl-4-[8-({(2S)-2-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]-2-hydroxyethyl}amino)-6-(1-methyl-1H-pyrazol-5-yl)imidazo[1,2-b]pyridazin-3-yl]benzamide 
• 73387-56-1 1-methyl-5-(4-methylphenyl)-1H-pyrazole 

Relevant articles and documents

Discovery of novel α1-adrenoceptor ligands based on the antipsychotic sertindole suitable for labeling as PET ligands

The synthesis and in vitro preclinical profile of a series of 5-heteroaryl substituted analogs of the antipsychotic drug sertindole are presented. Compounds 1-(4-fluorophenyl)-3-(1-methylpiperidin-4-yl)-5-(pyrimidin-5-yl)-1H- indole (Lu AA27122, 3i) and 1-(4-fluorophenyl)-5-(1-methyl-1H-1,2,4-triazol-3- yl)-3-(1-methylpiperidin-4-yl)-1H-indole (3l) were identified as high affinity α1A-adrenoceptor ligands with Ki values of 0.52 and 0.16 nM, respectively, and with a >100-fold selectivity versus dopamine D2 receptors. Compound 3i showed almost equal affinity for α1B- (Ki = 1.9 nM) and α1D- adrenoceptors (Ki = 2.5 nM) as for α1A, as well as moderate affinity for 5-HT1B (Ki = 13 nM) and 5-HT 6 (Ki = 16 nM) receptors, whereas 3l showed >40-fold selectivity toward all other targets tested. Based on in vitro assays for assessment of permeability rates and extent, it is predicted that both compounds enter the brain of rats, non-human primates, as well as humans, and as such are good candidates to be carried forward for further evaluation as positron emission tomography (PET) ligands.

Discovery of 1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxyphenyl]-3-(2, 4-difluorophenyl)urea (Nelotanserin) and Related 5-Hydroxytryptamine 2A Inverse Agonists for the Treatment of Insomnia

Insomnia affects a growing portion of the adult population in the U.S. Most current therapeutic approaches to insomnia primarily address sleep onset latency. Through the 5-hydroxytryptamine2A (5-HT2A) receptor, serotonin (5-HT) plays a role in the regulation of sleep architecture, and antagonists/ inverse-agonists of 5-HT2A have been shown to enhance slow wave sleep (SWS). We describe here a series of 5-HT2A inverse-agonists that when dosed in rats, both consolidate the stages of NREM sleep, resulting in fewer awakenings, and increase a physiological measure of sleep intensity. These studies resulted in the discovery of 1-[3-(4-bromo-2- methyl-2i/-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (Nelotanserin), a potent inverse-agonist of 5-HT2A that was advanced into clinical trials for the treatment of insomnia.

DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERTO

The present invention relates to certain pyrazole derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to